Skip to main content

Advertisement

SpringerLink
Log in

In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Iron plays a major role in the growth and virulence of ferrophilic organisms like Vibrio vulnificus. People who reside in the coastal areas with raw fish eating habits have a high risk of Vibrio infection and aggressive therapy can only reduce their mortality. We investigated the in vitro efficacy of ciprofloxacin, a bactericidal drug used in V. vulnificus patients, and the orally active iron chelator deferasirox against V. vulnificus infection. We performed in vitro time-kill studies on two ATCC strains and one clinical isolate of V. vulnificus collected from a patient admitted to Chosun University Hospital with either ciprofloxacin or iron chelator deferasirox alone and the two drugs in combination. The combination of an iron chelator plus an antibiotic creates a novel form of synergism at 24 h. The antimicrobial effect of deferasirox may be ascribed to its ability to deplete iron that would otherwise be used for bacterial growth. Combination therapy with ciprofloxacin plus deferasirox has potential clinical application by lowering the iron availability against a ferrophilic organism like V. vulnificus infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kim DM, Lym Y, Jang SJ, Han H, Kim YG, Chung CH et al (2005) In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus. Antimicrob Agents Chemother 49:3489–3491

    Article  CAS  PubMed  Google Scholar 

  2. Bross MH, Soch K, Morales R, Mitchell RB (2007) Vibrio vulnificus infection: diagnosis and treatment. Am Fam Physician 76(4):539–544

    PubMed  Google Scholar 

  3. Klontz KC, Lieb S, Schreiber M, Janowski HT, Baldy LM, Gunn RA (1988) Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981–1987. Ann Interm Med 109:318–323

    CAS  Google Scholar 

  4. Chiang SR, Chuang YC (2003) Vibrio vulnificus infection: clinical manifestations, pathogenesis, and antimicrobial therapy. J Microbiol Immunol Infect 36:81–88

    PubMed  Google Scholar 

  5. Simpson LM, Oliver JD (1983) Siderophore production by Vibrio vulnificus. Infect Immun 41:644–649

    CAS  PubMed  Google Scholar 

  6. Lankford CE (1973) Bacterial assimilation of iron. CRC Crit Rev Microbiol 2:273–331

    Article  CAS  Google Scholar 

  7. Kushner JP (1988) Hypochronic anemias. In: Wyngaarden JB, Smith LH (eds) Cecil textbook of medicine, vol 1, 18th edn. WB Saunders, Philadelphia, PA, pp 892–900

    Google Scholar 

  8. Bullen JJ, Rogers HJ, Spalding PB, Ward CG (2005) Iron and Infection: the heart of the matter. FEMS Immunol Med Microbiol 43:325–330

    Article  CAS  PubMed  Google Scholar 

  9. Kim CM, Park RY, Choi MH, Sun HY, Shin SH (2007) Ferrophilic characteristics of Vibrio vulnificus and potential usefulness of iron chelation therapy. J Infect Dis 195:90–98

    Article  CAS  PubMed  Google Scholar 

  10. Clinical and Laboratory Standards Institute (CLSI) (2008) Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement, vol 28, no 1. Document no. M100–S18. CLSI, Wayne, PA

  11. Chuang YC, Liu JW, Ko WC, Lin KY, Wu JJ, Huang KY (1997) In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus. Antimicrob Agents Chemother 41:2214–2217

    CAS  PubMed  Google Scholar 

  12. Kim DM, Yun NR, Chung JH, Ryu HH (2008) Time kill studies of antibiotics against a nalidixic acid resistant Salmonella enterica serotype Typhi. Infect Chemother 40:207–211

    Article  Google Scholar 

  13. Moland ES, Craft DW, Hong Sg, Kim SY, Hachmeister L, Sayed SD et al (2008) In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline–amikacin synergy. Antimicrob Agents Chemother 52:2940–2942

    Article  CAS  PubMed  Google Scholar 

  14. Tang HJ, Chang MC, Ko WC, Huang KY, Lee CL, Chuang YC (2002) In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus. Antimicrob Agents Chemother 46:3580–3584

    Article  CAS  PubMed  Google Scholar 

  15. Kim DM, Cho HS, Kang JI, Kim HS, Park CY (2008) Deferasirox plus ciprofloxacin combination therapy after rapid diagnosis of Vibrio vulnificus sepsis using real-time polymerase chain reaction. J Infection 57:489–492

    Article  Google Scholar 

  16. Kim CM, Park YJ, Shin SH (2007) A widespread deferoxamine-mediated iron-uptake system in Vibrio vulnificus. J Infect Dis 196(10):1537–1545

    Article  CAS  PubMed  Google Scholar 

  17. Kontoghiorghes GJ, Weinberg ED (1995) Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches. Blood Rev 9(1):33–45

    Article  CAS  PubMed  Google Scholar 

  18. Neupane GP, Kim DM (2009) Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus. Transfusion 49:1762–1769

    Article  CAS  Google Scholar 

  19. van Asbeck BS, Marcelis JH, van Kats JH, Jaarsma EY, Verhoef J (1983) Synergy between the iron chelator deferoxamine and the antimicrobial agents gentamicin, chloramphenicol, cefalothin, cefotiam and cefsulodin. Eur J Clin Microbiol 2:432–438

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors do not have any commercial interest or other association that might pose a conflict of interest.

This study was supported by research funds from Chosun University, 2009.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Internal Medicine, Chosun University, College of Medicine, 588 Seosuk-dong, Dong-gu, Gwangju, 501-717, Republic of Korea

    G. P. Neupane & D.-M. Kim

  2. Research Center for Resistant Cells, Chosun University, College of Medicine, Gwangju, Republic of Korea

    D.-M. Kim

Authors
  1. G. P. Neupane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D.-M. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D.-M. Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neupane, G.P., Kim, DM. In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus . Eur J Clin Microbiol Infect Dis 29, 407–410 (2010). https://doi.org/10.1007/s10096-010-0875-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-010-0875-5

Keywords

Search

Navigation